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Abstract The receptor for advanced glycation end-products
(RAGE)-mediated cellular activation through the mitogen-acti-
vated protein kinase (MAPK) cascade, activation of NF-UB and
Rho family small G-proteins, cdc42/Rac, is implicated in the
pathogenesis of in£ammatory disorders and tumor growth/meta-
stasis. However, the precise molecular mechanisms for the ini-
tiation of cell signaling by RAGE remain to be elucidated. In
this study, proteins which directly bind to the cytoplasmic C-ter-
minus of RAGE were puri¢ed from rat lung extracts using an
a⁄nity chromatography technique and identi¢ed to be extracel-
lular signal-regulated protein kinase-1 and -2 (ERK-1/2). Their
interactions were con¢rmed by immunoprecipitation of ERK-1/2
from RAGE-expressing HT1080 cell extracts with anti-RAGE
antibody. Furthermore, the augmentation of kinase activity of
RAGE-bound ERK upon the stimulation of cells with ampho-
terin was demonstrated by determining the phosphorylation level
of myelin basic protein, an ERK substrate. In vitro binding
studies using a series of C-terminal deletion mutants of human
RAGE revealed the importance of the membrane-proximal cy-
toplasmic region of RAGE for the direct ERK^RAGE interac-
tion. This region contained a sequence similar to the D-domain,
a ERK docking site which is conserved in some ERK substrates
including MAPK-interacting kinase-1/2, mitogen- and stress-ac-
tivated protein kinase-1, and ribosomal S6 kinase. These data
suggest that ERK may play a role in RAGE signaling through
direct interaction with RAGE.
9 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The receptor for advanced glycation end-products (RAGE)
is a member of the immunoglobulin superfamily of cell sur-
face molecules [1]. It is well known as a multi-ligand receptor
which interacts with various ligands including EN-RAGE/
S100A12 which is a member of the S100/calgranulin family
[2], amyloid-L [3,4], amphoterin [5] and advanced glycation
end-products (AGEs) [6].
RAGE is expressed in vascular smooth muscle cells, endo-
thelial cells, mononuclear phagocytes, mesangial cells, neu-
rons, and lung alveolar epithelial cells [7,8]. Engagement of
the ligands to RAGE induces expression of the receptor itself
and ampli¢es the pro-in£ammatory response leading to sus-
tained cellular activation and tissue dysfunction by the recep-
tor-dependent mechanism [9]. Although RAGE may not be
essential to the initial pathogenesis of disorders, the distribu-
tion patterns of RAGE and its ligands re£ect the involvement
of RAGE in the ampli¢cation or progression of various dis-
eases, such as diabetes [10,11], Alzheimer’s disease [3,4], in-
£ammation [2,9] and tumors [12].
The S100/calgranulins are a group of closely related pro-
teins with two EF-hand domains and have a central role as a
mediator in in£ammatory disorders [13^15]. Hofmann et al.
[2] have reported that RAGE^S100/calgranulin interaction
participates in immune/in£ammatory responses.
In Alzheimer’s disease, deposition of amyloid-L-containing
plaques in the brain correlates with progressive neuronal dys-
function leading to dementia. Neuronal RAGE has been
shown to interact with amyloid-L resulting in cellular oxidant
stress and triggering a pro-in£ammatory pathway leading to
activation of microglial cells [3,4].
AGEs resulting from non-enzymatic glycation of proteins
and lipids gradually accumulate during normal aging and at
an accelerated rate in diabetes. Hyperglycemia-driven accu-
mulation of AGEs has been suggested to be involved in the
pathogenesis of diabetic vascular disease. The interaction of
AGEs with RAGE results in perturbation of a variety of
vascular homeostatic functions and has been shown to play
a major role in the development of diabetic vasculopathy
[6,11].
Amphoterin, also called high mobility group 1, is a member
of the family of high mobility group non-histone chromosom-
al DNA binding proteins [16^19]. When amphoterin is re-
leased from cells, its engagement with RAGE promotes neu-
rite outgrowth of neuronal cells in the nervous system [20,21]
as well as tumor growth and metastasis [12]. Srikrishna et al.
have reported that interaction between amphoterin and
RAGE depends on the carboxylated N-glycans of RAGE
[22]. Interestingly, they showed that the glycans on RAGE
have an important role in RAGE-dependent neurite out-
growth of N18 neuroblastoma cells.
Thus, RAGE interacts with a range of ligands leading to
diverse cellular responses varying from cytokine secretion and
increased cellular oxidant stress to cell survival, di¡erentia-
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tion, and proliferation. These responses are dependent on
RAGE-mediated signals and gene expression. It has been
shown that RAGE ligation by its ligands results in the acti-
vation of multiple signaling pathways, including the mitogen-
activated protein kinase (MAPK) cascade [23], cdc42/Rac [20],
and activation of NF-UB and Sp1 [20,23^25]. Several gene
targets which are upregulated upon the activation of RAGE
signaling pathways have been identi¢ed, including interleukin-
6 [26], vascular endothelial cell growth factor [24,27], vascular
cell adhesion molecule-1 [28] in endothelial cells, macrophage/
colony-stimulating factor [4], tissue factor [29] in macrophage,
and Bcl-2 [30] in neuronal cells. However, the molecular basis
leading to the activation of these signaling pathways after
RAGE/ligand ligation remains to be elucidated. It was re-
ported that receptors with a highly charged cytosolic tail are
critical for RAGE-mediated cellular activation because the
cytosolic C-terminally truncated RAGE serves as a dominant
negative receptor for blocking the e¡ects of RAGE-dependent
cellular activation [9,12,20]. These observations evidently in-
dicate the existence of a signaling molecule(s) which associates
with the cytoplasmic domain of RAGE.
In the present study, we aimed to identify the downstream
e¡ector(s), which can interact with the cytoplasmic tail of
RAGE, using a⁄nity puri¢cation techniques. Rat lung was
used as a starting material for the puri¢cation of RAGE bind-
ing proteins, because the RAGE protein is expressed mainly
in the lung tissue. Finally, we identi¢ed extracellular signal-
regulated kinase-1 and -2 (ERK-1/2) as RAGE binding pro-
teins and demonstrated their interactions in the cells. Our
results may contribute to the understanding of the molecular
basis of RAGE signaling.
2. Materials and methods
2.1. Cell culture and transfection
Human ¢brosarcoma HT-1080 and mouse melanoma B16-F10 cells
were maintained in medium A (RPMI 1640 medium supplemented
with 50 U/ml penicillin, 50 Wg/ml streptomycin, 2 mM glutamine,
and 10% v/v fetal calf serum) at 37‡C in a humidi¢ed 5% CO2^95%
air incubator. The cDNA fragment encoding the full-length human
RAGE (NCBI accession number: 26787960) was ampli¢ed with
5P-TTGAATTCAGGATGGCAGCCGGAACAGCAG-3P and 5P-TT-
CTCGAGTCAAGGCCCTCCAGTACTAC-3P. The ampli¢ed cDNA
was digested with EcoRI and XhoI, and inserted into a mammalian
expression vector, pcDNA3.1+ (Invitrogen, Carlsbad, CA, USA) that
had been digested with the same restriction enzymes. HT1080 cells
were transfected with the resultant plasmid, pcDNA-hRAGE using
LipofectAMINE 2000 according to the manufacturer’s instructions
(Invitrogen). HT1080-hRAGE cells stably expressing human RAGE
were selected and maintained in medium A supplemented with 0.5 mg/
ml G418 (Life Technologies, Japan).
2.2. Recombinant proteins and antibodies
Fusion proteins with glutathione S-transferase (GST) or a hexahis-
tidine tag were expressed by employing pGEX-6P1 (Amersham-Phar-
macia) and pPROEX-HTa (Invitrogen) in the BL21(DE3) strain of
Escherichia coli (Novagen, Madison, WI, USA).
Recombinant CR43-GST fusion protein was prepared and puri¢ed
as follows. The cDNA fragment encoding the cytoplasmic C-terminal
domain (aa 362^404) of human RAGE was subcloned into the Bam-
HI-XhoI site downstream of the sequence for GST in pGEX-6P1,
yielding pGEX-CR43. This plasmid was transformed into the
BL21(DE3) strain of E. coli and induced with isopropyl-L-D-thioga-
lactopyranoside to produce GST fusion proteins. The bacteria cells
were suspended in phosphate-bu¡ered saline (PBS) and vigorously
sonicated followed by centrifugation at 10 000Ug for 30 min. The
resulting supernatants were applied on a glutathione beads column
and then eluted with bu¡er E (50 mM Tris^HCl, pH 7.6, 120 mM
NaCl, 10 mM glutathione). Puri¢ed GST fusion proteins were dia-
lyzed against PBS.
For preparing two C-terminal deletion mutants of CR43-GST
(CR34-GST and CR18-GST fusion proteins), nucleotides correspond-
ing to Gln379 and Glu395 of human RAGE in plasmid pGEX-CR43
were point-mutated into the stop codon using oligonucleotides:
CR34-sense, 5P-CAGTCGGAGGAACCTTAGGCAGGCGAGAGT-
AG-3P ; CR34-antisense, 5P-CTACTCTCGCCTGCCTAAGGTTCC-
TCCGACTG-3P ; CR18-sense, 5P-GAAGGCCCCAGAAAACTAG-
GAGGAAGAGGAGG-3P ; CR18-antisense, 5P-CCTCCTCTTCCTC-
CTAGTTTTCTGGGGCCTTC-3P (QuikChange1 site-directed muta-
genesis kit, Stratagene, La Jolla, CA, USA), yielding pGEX-CR34
and pGEX-CR18 respectively. Recombinant CR34-GST and CR18-
GST proteins were prepared and puri¢ed as described above.
C-terminally truncated recombinant human amphoterin was ex-
pressed as a fusion protein with a hexahistidine tag to its C-terminus
and puri¢ed from E. coli BL2(DE3) (Novagen) harboring the
pPROEX-hAmphoterinvC plasmid using a Ni-NTA agarose column
(Qiagen, Japan). pPROEX-hAmphoterinvC was constructed by insert-
ing the cDNA encoding human amphoterin (1^185 aa) into pPROEX-
HTa. Speci¢c binding of the C-terminally truncated amphoterin with
RAGE was con¢rmed by a binding assay.
The monoclonal antibody against RAGE was prepared as follows.
Recombinant human soluble RAGE protein (319 aa) was puri¢ed
from the culture supernatant of baculovirus-infected ExpresSF+1
cells with the FPLC system (Amersham-Pharmacia) using HiTrap1
SP and HiTrap1 Butyl columns. WKY/NCrj rats were immunized
with the recombinant RAGE protein. Lymph node cells were har-
vested from the immunized rats and fused with mouse myeloma cells
SP2/O-Ag14 (Dainippon Seiyaku, Japan). One of the established
monoclonal antibodies was named 11F2. The RAGE polyclonal anti-
body raised against a peptide corresponding to the N-terminal immu-
noglobulin variable region-like domain of human RAGE was kindly
provided by Metabolism and Cardiovascular Diseases, Novartis Phar-
maceuticals Corp. (East Hanover, NJ, USA). These antibodies were
a⁄nity-puri¢ed from the ascites £uids of nude mice or the sera of
rabbits.
Rabbit anti-ERK (K-23, #sc-94) and anti-active0 MAPK polyclon-
al antibodies (#V8031) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) and Promega (Madison, WI, USA),
respectively.
2.3. A⁄nity puri¢cation and amino acid sequencing of RAGE binding
protein
Lung tissues obtained from 10 male Wistar rats were homogenized
with T-PER Tissue Protein Extraction Reagent (Pierce Biotechnology,
Rockford, IL, USA) containing a cocktail of protease inhibitors,
Complete1 (Roche, Mannheim, Germany), and the homogenate
was centrifuged at 100 000Ug for 1 h at 4‡C. The supernatant (150
ml) was recovered and used as a lung extract. Glutathione-Sepharose
4B (Amersham Pharmacia) saturated with the recombinant CR43-
GST fusion protein or control GST was used to a⁄nity-purify the
CR43 binding proteins. The rat lung extract (total protein: 1050 mg)
was pre-cleared with GST-glutathione beads (bead volume: 150 Wl)
followed by incubation with 50 Wl of CR43-GST-glutathione beads by
gently rotating for 2 h at 4‡C. The beads were washed ¢ve times with
10 ml of ice-cold extraction bu¡er diluted with an equal volume of
PBS, and further washed twice with PBS. Then, proteins were eluted
with bu¡er E. After the eluate was dialyzed against PBS and concen-
trated, the protein solution containing p39 and p43 was subjected to
two-dimensional polyacrylamide gel electrophoresis (2D-PAGE: iso-
electric focusing GE and SDS^PAGE) in the denaturing conditions.
The bands of p39 and p43 stained with Coomassie brilliant blue R250
were cut out and washed extensively with MilliQ water. Each piece of
the gel blocks was sent to APRO Science Inc. (Tokushima, Japan) for
their internal amino acid sequencing. In brief, p39 and p43 were
digested with trypsin. The resulting peptides were separated onto a
column of TSK gel ODS-80Ts QA with a 0^90% gradient of acetoni-
trile in 0.1% tri£uoroacetic acid and then the peptide sequences de-
termined with the Procise 494 HT protein sequencing system (Applied
Biosystems Japan).
2.4. Immunoprecipitation, Western blotting and in vitro kinase assay
HT1080-hRAGE cells were grown in medium A until 80% con£u-
ence. Cells (1.5U107) were washed with serum-free RPMI 1640 me-
dium supplemented with 1% bovine serum albumin (Sigma, St. Louis,
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MO, USA) and starved in the same medium for 8 h. Then, ampho-
terin (25 Wg/ml) was added to the cell culture and incubated for a
certain period. HT1080-hRAGE cells were lysed with a Triton X-100
solubilization bu¡er composed of 20 mM Tris^HCl (pH 7.6), 120 mM
NaCl, 1 mM EDTA, 50 mM sodium £uoride, 10 mM sodium pyro-
phosphate, 10 mM sodium L-glycerophosphate, 1 mM sodium ortho-
vanadate, 1% Triton X-100 containing Complete1 on ice. The lysate
was preincubated with protein A-Sepharose (Amersham Pharmacia)
for 1 h at 4‡C and then incubated with a rabbit anti-RAGE IgG
coupled to protein A-Sepharose. After 2 h incubation at 4‡C, the
beads were washed four times with a Triton X-100 solubilization bu¡-
er. The immunoprecipitates were then used for further analyses, such
as Western blotting probed with anti-ERK antibody and in vitro ki-
nase assay. In brief, for the analysis of ERK binding to RAGE, the
immunocomplexes were separated in SDS^PAGE gels and electro-
transferred onto polyvinylidene di£uoride ¢lters. Filters were blocked
with 5% non-fat dry milk powder and incubated with an anti-ERK
polyclonal antibody, K-23 (#sc-94, Santa Cruz) followed by incuba-
tion with a peroxidase-conjugated anti-rabbit IgG antibody
(NA9340V, Amersham Biosciences), and then the bands of ERK pro-
teins were visualized with enhanced chemiluminescence (Amersham
Biosciences). ERK kinase activities contained in the RAGE immuno-
precipitates were measured in vitro using a MAPK assay kit (Upstate,
Lake Placid, NY, USA). The immunoprecipitates (5 Wl of bead vol-
ume) were further washed twice with 75 Wl of 1Uassay dilution bu¡er
(ADB) and supplemented with 10 Wl of each reagent, 1UADB, kinase
inhibitor cocktail (protein kinase (PK) C, PKA inhibitor peptides and
compound R24571), MAPK substrate cocktail (myelin basic protein,
MBP), and Mg/ATP cocktail. After incubation at 30‡C for 20 min in
a shaking incubator, a 2.5 Wl aliquot of the reaction mixture was
separated by SDS^PAGE and subjected to Western blotting, in which
phosphorylation of MBP was detected with anti-phospho MBP anti-
body (Upstate).
2.5. In vitro binding experiments
Each of the extracts which were prepared from rat lung tissues,
HT1080 and B16 cells were incubated with 25 Wg of CR43 on gluta-
thione-Sepharose beads (bead volume: 5 Wl) for 2 h at 4‡C. The beads
were washed three times with wash bu¡er composed of 10 mM Tris^
HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 0.5% v/v Triton X-100,
and then SDS sample bu¡er was added. The resultant eluate was
subjected to SDS^PAGE followed by Western blotting as described
before.
In the experiments using the recombinant proteins, phosphorylated
and non-phosphorylated ERK-2 (#SE-137 and #SE-139, Biomol Re-
search Laboratories, Butler Pike, PA, USA), 25 Wg of CR43 on glu-
tathione-Sepharose beads (5 Wl) was added into 300 Wl of binding
bu¡er (10 mM Tris^HCl, pH 7.6, 150 mM NaCl, 1% w/v bovine
serum albumin, 0.5% v/v Triton X-100) containing 250 ng of phos-
phorylated ERK or non-phosphorylated ERK and incubated for 2 h
at 4‡C, and then the beads were washed and the bound proteins were
eluted as described above. One tenth of each eluate was used for
Western blotting analysis.
3. Results
3.1. Identi¢cation and puri¢cation of RAGE-associated proteins
To identify the molecules that speci¢cally bind to CR43, the
C-terminal cytoplasmic domain of RAGE, the rat lung extract
was incubated with CR43-GST a⁄nity beads. The proteins
bound to the beads were co-eluted with CR43-GST by adding
glutathione. Finally, two proteins with molecular masses of
approximately 43 kDa (p43) and 39 kDa (p39) were detected
in the glutathione eluate from a CR43-GST column but not
from a control GST column (Fig. 1A); therefore, they were
further puri¢ed by 2D-PAGE and subjected to amino acid
sequencing. Database searching of the determined sequences
(GTAGVVPVVPGE from p43, IEVEQALAHPYL from p39)
revealed that p43 and p39 were ERK-1 and -2, respectively.
The speci¢c interaction of ERK with CR43-GST was con-
¢rmed by Western blotting using an antibody speci¢c to phos-
phorylated ERK-1/2 (Fig. 1B), whereas there was no interac-
tion of CR43-GST with c-Jun N-terminal kinase (JNK) and
p38 MAPK (data not shown). It was also demonstrated that
ERK-1/2 from human ¢brocarcinoma HT-1080 and mouse
melanoma B16-F10 cells as well as ERK-1/2 from the rat
lung extract bound to CR43-GST protein.
Fig. 1. Identi¢cation of p43 (ERK-1) and p39 (ERK-2) as RAGE binding proteins. A: A⁄nity puri¢cation of p43 and p39. The rat lung ex-
tract which was prepared as described in Section 2 was subjected to a⁄nity binding to GST beads (lane 1) or human CR43-GST (lane 2)
beads, and the bound proteins were eluted by the addition of bu¡er E containing glutathione. The eluates were subjected to SDS^PAGE, fol-
lowed by Coomassie brilliant blue staining. B: Identi¢cation of the RAGE binding proteins. The p39 and p43 proteins were recovered from
the pieces of gel blocks, digested with trypsin and their N-terminal amino acid sequences determined. The same eluates as shown in A were
also probed in a Western blot with the antibody speci¢c for phosphorylated ERKs (anti-active MAPK). Lane 1, GST; lane 2, CR43-GST.
C: HT1080 and B16-F10 cells were extracted with 1% Triton X-100 and probed with anti-active MAPK. In vitro binding experiments were car-
ried out using cell extracts. Lane 1, GST (HT1080 cells); lane 2, CR43-GST (HT1080 cells) ; lane 3, GST (B16 cells) ; lane 4, CR43-GST (B16
cells).
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Next, we examined whether their interaction is direct or
mediated by any adapter protein which can bind both
RAGE and ERK. As shown in Fig. 2, both phosphorylated
and non-phosphorylated forms of the recombinant ERK-2
protein interacted with CR43-GST protein, indicating that
CR43-GST directly binds with ERK. In our experimental
conditions, their interaction appeared to be independent of
the phosphorylation of ERK. Furthermore, we obtained the
same results when a fusion protein (mouse CR43-GST) of the
cytoplasmic domain of mouse RAGE with GST was used
instead of human CR43-GST for the in vitro binding assay,
suggesting a conserved ERK binding ability of RAGE be-
tween species.
3.2. Association of ERK with RAGE in cells
To examine the interactions between RAGE and ERK in
cells, HT1080-hRAGE cells were solubilized with 1% Triton
X-100 and immunoprecipitated with an anti-RAGE polyclon-
al antibody. The resulting immunoprecipitates were probed
with an anti-ERK antibody. As shown in Fig. 3A, ERK
was co-immunoprecipitated with an anti-RAGE polyclonal
antibody after the engagement of amphoterin to RAGE, in-
dicating that the ligand engagement can enhance the RAGE^
ERK interaction in cells expressing RAGE. A maximal signal
of ERK^RAGE interaction was observed at 20 min after ex-
posure of the cells to amphoterin.
In order to demonstrate the kinase activity of ERK associ-
ated with RAGE, RAGE immunoprecipitates were prepared
from parental HT1080 as well as HT1080-hRAGE cells with
or without amphoterin stimulation. MBP was used as a sub-
strate for phosphorylation by ERK in the presence of some
inhibitors for other kinases such as PKA and PKC. As shown
in Fig. 3B, higher activities of RAGE-bound MAPK were
detected in the RAGE immunoprecipitates from HT1080-
hRAGE cells (lanes 4^7) compared with those from control
HT1080 cells (lanes 1^3). These kinase activities were detected
at 20 min after cell exposure to amphoterin and remained high
for up to 80 min. Thus, the results indicate that amphoterin
binding to the cell surface induced intracellular ERK^RAGE
interactions and enhanced ERK kinase activity.
3.3. Domain involved in ERK and RAGE interaction
We next examined the e¡ect of the C-terminal deletion of
RAGE on the binding of ERKs by in vitro binding assay
(Fig. 4A). The results indicated that the 18 amino acids in
the juxtamembrane region (CR18) are su⁄cient for binding
ERK (Fig. 4B). We also found that the membrane-proximal
regions corresponding to amino acid residues 362^374 of
RAGEs contain a sequence motif similar to the ERK docking
sites of MAPK-interacting kinase 1/2 (MnK1/2), mitogen- and
stress-activated protein kinase 1 (MSK1), and ribosomal S6
kinases pp90rsk (RSKs) (Fig. 4C).
4. Discussion
RAGE has been reported to activate some intracellular sig-
nals including the MAPK cascade and cdc42/Rac pathway
leading to ampli¢cation or progression of various diseases
Fig. 2. Both phosphorylated and non-phosphorylated ERK-2 di-
rectly interact with CR43-GST protein. Phosphorylated (lanes 2, 4,
and 6) and non-phosphorylated (lanes 1, 3, and 5) recombinant
ERK-2 were mixed with GST (lanes 1 and 2), human CR43-GST
(lanes 3 and 4), or mouse CR43-GST (lanes 5 and 6) proteins
bound to glutathione-Sepharose beads and incubated for 2 h at
4‡C. Their eluates and recombinant ERK proteins (lanes 7 and 8)
were boiled with SDS sample bu¡er and separated by SDS^PAGE,
followed by Western blotting (WB) using (A) anti-ERK antibody,
K-23 or (B) anti-active phosphorylated MAPK polyclonal antibod-
ies.
Fig. 3. ERK interacts with RAGE in HT1080 cells. A: RAGE^
ERK interaction in HT1080 cells stably transfected with human
RAGE cDNA. The cells (HT1080-hRAGE) were untreated (lane 1)
or treated with amphoterin (25 Wg/ml) for 5, 20, or 80 min (lanes 2^
4, respectively) and then solubilized with Triton X-100, and the
RAGE was immunoprecipitated (IP) with a rabbit anti-RAGE poly-
clonal antibody. The resulting immunoprecipitates were then ana-
lyzed by Western blotting (WB) using anti-ERK (K-23) or anti-
RAGE monoclonal (11F2) antibodies. B: Kinase activities in
RAGE immunoprecipitates. The RAGE immunoprecipitates were
prepared from parental HT1080 (lanes 1^3) and HT1080-hRAGE
cell lysates (lanes 4^7) in the same experimental conditions as in A.
The cells were untreated (lane 4) or treated with amphoterin for 5,
20, or 80 min (lanes 1^3 and 5^7) prior to solubilization. Then,
they were subjected to in vitro phosphorylation assay with MBP as
an ERK substrate. The phosphorylation of MBP was detected by
probing with anti-phospho-MBP antibody (clone P12, #05-429, Up-
state) according to the manufacturer’s instructions.
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including diabetic vascular complications, in£ammation, and
tumor growth/metastasis. Concerning RAGE intracellular sig-
naling pathways, the cytoplasmic region of RAGE is consid-
ered to be responsible for the binding of signaling molecule(s)
[9,20]. However, no signaling molecule which binds directly to
the RAGE cytoplasmic region has been identi¢ed yet.
In the present study, using an a⁄nity chromatography tech-
nique, we identi¢ed ERK-1/2 as RAGE binding proteins from
the rat lung extract. Direct binding capacity of the conserved
ERK-2 with RAGE regardless of the phosphorylation status
of ERK-2 was demonstrated between two species by the bind-
ing assay in vitro using recombinant ERK-2. Whether ERK-1
binds RAGE directly or through ERK-2 was not clari¢ed,
because the same experiment was not done with ERK-1.
However, ERK-1 binding could also be important for
RAGE signal transduction, because many studies have indi-
cated that both ERK-1/2 could be involved downstream of
RAGE signal transduction [21,23,31].
To con¢rm the interaction between RAGE and ERK in
cells, immunoprecipitation and immunoblotting analysis
were carried out using anti-RAGE and anti-ERK antibodies.
ERK-1/2 were co-immunoprecipitated with RAGE by anti-
RAGE IgG from HT1080-hRAGE cell extract. Interestingly,
RAGE^ERK interactions in HT1080-hRAGE cells were de-
tected when the cells were stimulated with amphoterin, indi-
cating that the RAGE^ERK association depends upon the
stimulation of RAGE by the ligand. Whether the binding of
amphoterin to RAGE causes a conformational change of
RAGE and/or its clustering, which leads to RAGE binding
of ERK, is not clear in detail at present. However, it is known
that the receptor clustering induced by ligand engagement is
critical for the receptor activation leading to transmission of
signals into the nuclei of cells [32]. Examples of this include
homodimer formation of epidermal growth factor receptor
[33] and oligomerization of tumor necrosis factor receptor
[32^35]. In our a⁄nity puri¢cation system using the RAGE^
GST fusion protein, RAGE immobilization on the beads pos-
sibly formed a high density of RAGE providing the ERK
binding site(s) which could be created by the ligand-induced
activation of native RAGE in the cell.
It was also examined whether or not enhancement of ERK
by a ligand treatment could be detected by measuring the
kinase activity of ERK co-precipitated with the RAGE im-
munoprecipitates. We observed increased ERK kinase activ-
ities in RAGE immunoprecipitates from 20 to 80 min after the
amphoterin treatment of cells. However, RAGE binding
ERKs were detected within 5 min after the amphoterin treat-
ment and the levels reached a maximum at 20 min, and then
decreased to the same level of that at 5 min by 80 min. There
was an apparent di¡erence in the time course between the
level of ERK binding with RAGE and the ERK kinase ac-
tivity. It may be considered that the whole ERK binding with
RAGE reached a peak early, while phospho-ERK binding or
phosphorylation of ERK was still increasing up to 80 min.
Although we cannot completely exclude the possibility of the
presence of other kinases in addition to ERK in the immuno-
precipitates, our present results strongly suggest the ligand-
induced interaction of ERK with RAGE leads to the enhance-
ment of ERK kinase activity in the cell.
We next addressed ERK binding sites in the cytoplasmic
region of RAGE by in vitro binding experiments using the
two deletion mutants of CR43. The primary structure of the
cytoplasmic region of RAGE, which is critical for signal
transduction, is conserved in various species including human,
bovine, mouse, and rat. This region is further divided into at
least three parts by aligning the amino acid sequences of RA-
GEs: a membrane-proximal 17 amino acid domain relatively
rich in basic amino acids, a central 17 amino acid domain rich
in glutamic acid and low-conserved C-terminus of nine resi-
dues. We found that the membrane-proximal domain of the
Fig. 4. The membrane-proximal region in the C-terminal cytoplas-
mic domain of RAGE is required for interaction with ERK-1 and
-2. A: The constructs of various versions of RAGE are shown sche-
matically. Various deletion mutants of human RAGE fused with
GST were produced and a⁄nity-puri¢ed with glutathione-Sepharose
beads. N, N-terminus; C, C-terminus; TM, transmembrane. B: Rat
lung extracts were mixed with glutathione-Sepharose beads with im-
mobilized CR18, CR34, or CR43-GST (CBB, gel stained with Coo-
massie brilliant blue R-250). Bound proteins were eluted with bu¡er
E, and the eluate was resolved by SDS^PAGE, followed by probing
with anti-ERK polyclonal antibody, K-23 (WB, western blot).
C: Sequence motif required for interaction of RAGE with ERKs.
Alignment of the ERK docking sites of MnK1/2, MSK1, and
RSK1, 2, and 3 with the cytoplasmic membrane-proximal regions of
human and mouse RAGEs. Conserved residues within the putative
binding sites are highlighted. For consensus sequence: x, any amino
acid; +, basic amino acids; and P, hydrophobic amino acids. NCBI
accession numbers: mouse MnK1, 1929059 (EMBL, Y11091);
mouse MnK2, 1929061 (EMBL, Y11092); human MSK1, 3411157
(accession, AF074393); rat RSK1, 2117822 (PIR, A53300); mouse
RSK2, 125691 (SwissProt, P18654); human RSK3, 2117823 (PIR,
A57459); human RAGE, 26787960 (accession, NM_001136); mouse
RAGE, 6671524 (accession, NM_007425).
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C-terminal cytoplasmic region of RAGE is required for the
direct ERK^RAGE interaction. Recently, some ERK sub-
strates have been shown to contain motifs that mediate high
a⁄nity interactions with ERK. Such examples are a docking
site D-domain in phosphatases [36,37], transcription factors
[38], phosphodiesterase [39] and kinases [40] and an FXFP
motif in ETS transcription factors of the Elk subfamily
[38,40]. The region required for the direct ERK^RAGE inter-
action has a similarity to the D-domain-like ERK docking
sites of MnK1/2, MSK1, and RSKs, which are characterized
by a cluster of basic residues [39^43]. Smith et al. [42] reported
that carboxy-terminal tails of the RSKs contain an ERK
docking site and interact with ERK but not with JNK or
p38 MAPK. The number and placement of lysine and argi-
nine residues within the conserved region correlate with the
speci¢city for activation by ERK in vivo. We also con¢rmed
that RAGE speci¢cally binds with ERK but not with JNK or
p38 MAPK (data not shown).
Our results and others’ previous observations on ERK-in-
teracting molecules suggest that RAGE is one of the ERK
substrates. However, in the cytoplasmic region of RAGE,
there is neither a conserved Ser or Thr residue nor a phos-
phorylation site motif, Pro-X-(Ser/Thr)-Pro which ERK can
recognize. Further, ERK bound directly with RAGE regard-
less of its phosphorylation status. These observations suggest
that RAGE is not an ERK substrate but stabilizes ERK
under the proximal region of the plasma membrane and leads
to activation of the interaction between ERK and its sub-
strates. On the other hand, the cytoplasmic central region of
RAGE, which was not required for binding to ERK, is highly
conserved with a cluster of glutamic acid among species, sug-
gesting the possibility of the existence of an additional binding
molecule(s). However, we detected only ERK as a RAGE
binding protein in our experimental conditions in vitro.
Thus, our data together with previous observations suggest
that RAGE-mediated modulation of ERK [44^46], for in-
stance (prolonged) activation of ERK, altering its subcellular
localization/substrate speci¢city, and cross-talking with other
intracellular signals, may result in sustained activation of cells
and tissue dysfunction via its downstream e¡ectors such as
NF-UB [25]. Further studies will be required to examine our
hypothesis that (i) ligand-induced translocation of ERKs to
the plasma membrane through RAGE might enable them to
be e⁄ciently phosphorylated by MEK. Then, (ii) ERK phos-
phorylates other protein(s) bound on RAGE which serves as a
sca¡olding protein like kinase suppressor of Ras [47,48] and
leads to the activation of diverse signaling.
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